How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    Are the recommendations sound and a suitable basis for guidance to the NHS?
The content on this page is not current guidance and is only for the purposes of the consultation process.

Olaparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer

Closed for comments This consultation ended on at   Request commenting lead permission

1 Recommendations

1.1 Olaparib is not recommended, within its marketing authorisation, for maintenance treatment of relapsed, platinum-sensitive high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer that is in response to platinum-based chemotherapy in adults.

1.2 This recommendation relates to the tablet formulation of olaparib. It is not intended to affect treatment with olaparib that was started in the NHS before this guidance was published. People having treatment outside this recommendation may continue without change to the funding arrangements in place for them before this guidance was published, until they and their NHS clinician consider it appropriate to stop.

Why the committee made these recommendations

Clinical trials show that olaparib extends the time until cancer progresses compared with routine surveillance. However, the cost-effectiveness estimates are substantially above the range normally considered cost effective. Olaparib does not meet NICE's end-of-life or Cancer Drugs Fund criteria. Therefore, it is not recommended.